COMMON IMATINIB: A BUDGET-FRIENDLY ALTERNATIVE?

The arrival of common imatinib represents a significant chance for patients battling a certain type of cancer and other diseases. Original brand-name imatinib, often referred to as Gleevec, carries a considerable price cost, frequently making it accessibility for some individuals. Common versions